Prescribing COVID-19 treatments: what we should never forget.
作者信息
Tunesi S, Bourgarit A
机构信息
Sorbonne Paris-Nord University (Paris 13), Bobigny, France; Inserm, UMR 1135 CIMI, Paris, France; APHP, HUPSSD, Internal medicine department, Bondy, France.
Sorbonne Paris-Nord University (Paris 13), Bobigny, France; Inserm, UMR 1135 CIMI, Paris, France; APHP, HUPSSD, Internal medicine department, Bondy, France.
出版信息
J Infect. 2020 Aug;81(2):e85. doi: 10.1016/j.jinf.2020.05.018. Epub 2020 May 13.
Abstract
摘要
相似文献
1
Prescribing COVID-19 treatments: what we should never forget.
J Infect. 2020 Aug;81(2):e85. doi: 10.1016/j.jinf.2020.05.018. Epub 2020 May 13.
2
Statins in coronavirus outbreak: It's time for experimental and clinical studies.
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
3
Is the type of diabetes treatment relevant to outcome of COVID-19?
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
4
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
5
COVID-19: Stay Cool toward Corticosteroids.
Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.
6
Psychopharmacology of COVID-19.
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
7
Chloroquine and hydroxychloroquine in covid-19.
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
8
Erythema multiforme in the context of SARS-Coronavirus-2 infection.
Med Clin (Barc). 2020 Aug 14;155(3):141. doi: 10.1016/j.medcli.2020.04.016. Epub 2020 May 8.
9
Sofosbuvir for COVID-19 infection: A potential candidate.
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
10
Purposing Saikosaponins for the treatment of COVID-19.
Med Hypotheses. 2020 Jul;140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.
引用本文的文献
1
Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
J Infect. 2020 Aug;81(2):e117-e119. doi: 10.1016/j.jinf.2020.05.058. Epub 2020 May 28.
本文引用的文献
1
Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence.
BMJ. 2020 Apr 1;369:m1335. doi: 10.1136/bmj.m1335.
2
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
3
Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience.
Anesthesiology. 2020 Jun;132(6):1317-1332. doi: 10.1097/ALN.0000000000003296.
4
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
5
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
6
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
7
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
8
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019.
Zotero 插件